Improvement of in Vitro Fertilization Implantation by Soluble CD146 Dose in Embryonic Culture Environment

• Conditions: in Vitro Fertilization

• Registration Number: NCT03785119
• Lead Sponsor: Assistance Publique Hopitaux De Marseille

Brief Summary

The study of implantation potential of the embryo stay a priority in In Vitro Fertilization (IVF). Indeed, the selection of embryos to transfer is actually based in routine check on morphologic criteria, approved by literature but not perfect. Implantation's markers identification, allowing to choose the embryo(s) to transfer and then decrease pregnancy failure, represent a major issue in IVF, not any biomarker being approved yet.

Among factors regulating embryonic implantation, investigators have recently proposed soluble CD146, coming from proteolytic cleavage of the CD146 membrane, angiogenic bond molecule.

In a monocentric study about 222 transferred embryos at the end of IVF try, investigators showed that the sCD146 dose in the embryonic culture environment reflected the implantation ability of embryo, a high rate showing a low implantation potential and this independently of the embryonic quality. A multicentric prospective study is now required to confirm the utility of this dosage in clinical practice.

Primary objective : Compared 2 frozen embryo transfer (FET) strategies in terms of implantation efficiency, according to choice method of embryo to be transferred :

* Group A : Standard strategy : Depending on embryonic quality according to criteria currently selected.

* Group B : Experimental strategy : Association of embryonic quality according to criteria currently selected and of sCD146 rate.

Expected Results :

* Demonstrate a beginning pregnancy test significantly superior in Group B compared to Group A.

* Confirmed that sCD146 is an independent biomarker of morphologic embryonic quality (actual selection criteria) and represent a complementary criteria to choose embryos to transfer.

Methodology :

- Multicentric prospective study with 2 groups of Frozen Embryo Transfer (FET); The calculation of the number of staff required includes 151 couples per group.

For this will be include for 24 months, couples benefiting of freezing at least one of the two embryos and transfer of only one FET.

* Test the same day of environment freezing where frozen embryos were cultivated. sCD146 dosage by ELISA technic (Enzyme Linked ImmunoSorbent Assay) in thus culture environment before FET.

* Implantation potential analyze of each transfer embryo (FET) according to sCD146 rate.

* Following of the FET future(pregnancy, childbirth) : maximum 9 months after attempt to each included couple.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-12
• Study First Submitted: 2018-12-17
• Study First Submitted QC: 2018-12-19
• Last Update Submitted: 2018-12-19
• Study First Posted: 2018-12-24
• Last Update Posted: 2018-12-24
• Study Start: 2019-01
• Primary Completion: 2023-01
• Study Completion: 2023-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 318

Inclusion Criteria

• Women aged [18;42] years
• Men aged > 18 years
• Trying an IVF with :
• Frozen supernumerary embryo after fresh embryo transfer realised at the end of the try or frozen embryo (frozen all), without immediately transfer possibility (ovulation hyperstimulation context/ hyperprogesteronemia for example)
• Freezing at least 2 embryos frozen separately (1/vial)
• Whatever attempt rank
• Whatever MAP (Medically Assisted Procreation) technics (IVF/ICSI)
• Potential transfer of one frozen embryo
• Volunteer couples to participate at the study, received informations about this protocol and giving both their non opposition

Inclusion Criteria:

• FET realization in the selected population

Exclusion Criteria

• Refusal to participate at the study of at least one member of the couple
• Inclusion realized for a previous attempt
• IVF try with a third-party
• IVF try without embryo freezing
• Freezing only one embryo
• Non separately freezing of embryos (2/vial)
• Female patients <18 years and >42 years
• Male patients <18 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Beginner pregnancy rate at 1st transfer (%)	0 to 9 months after FET	Corresponds to number of defined pregnancy by plasmatic quantity of hCG (human chorionic gonadotropin) \>100 UI/l 15 days after FET/number of FET.

Secondary Outcome Measures

Name	Time	Method
Beginner pregnancy rate at 2nd or 3rd transfer	0 to 9 months after FET	Corresponds to number of defined pregnancy by plasmatic quantity of hCG \>100 UI/l 15 days after FET/number of FET.

Trial Locations

Locations (1)

Service de Biologie de la Reproduction; 🇫🇷 Marseille, France